SI2415771T1 - Derivat indolizina in njegova uporaba v medicinske namene - Google Patents
Derivat indolizina in njegova uporaba v medicinske nameneInfo
- Publication number
- SI2415771T1 SI2415771T1 SI201030404T SI201030404T SI2415771T1 SI 2415771 T1 SI2415771 T1 SI 2415771T1 SI 201030404 T SI201030404 T SI 201030404T SI 201030404 T SI201030404 T SI 201030404T SI 2415771 T1 SI2415771 T1 SI 2415771T1
- Authority
- SI
- Slovenia
- Prior art keywords
- medical purposes
- indolizine derivative
- indolizine
- derivative
- medical
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009086306 | 2009-03-31 | ||
| JP2009279976 | 2009-12-10 | ||
| EP10758713.1A EP2415771B1 (en) | 2009-03-31 | 2010-03-30 | Indolizine derivative and use thereof for medical purposes |
| PCT/JP2010/055692 WO2010113942A1 (ja) | 2009-03-31 | 2010-03-30 | インドリジン誘導体及びその医薬用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2415771T1 true SI2415771T1 (sl) | 2013-12-31 |
Family
ID=42828231
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201030404T SI2415771T1 (sl) | 2009-03-31 | 2010-03-30 | Derivat indolizina in njegova uporaba v medicinske namene |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8748452B2 (sl) |
| EP (1) | EP2415771B1 (sl) |
| JP (1) | JP5638513B2 (sl) |
| KR (1) | KR101772963B1 (sl) |
| CN (1) | CN102365281B (sl) |
| AU (1) | AU2010231615B2 (sl) |
| BR (1) | BRPI1013432B1 (sl) |
| CA (1) | CA2755132C (sl) |
| CY (1) | CY1114520T1 (sl) |
| DK (1) | DK2415771T3 (sl) |
| ES (1) | ES2429148T3 (sl) |
| HK (1) | HK1165793A1 (sl) |
| HR (1) | HRP20130846T1 (sl) |
| MX (1) | MX2011010395A (sl) |
| PL (1) | PL2415771T3 (sl) |
| PT (1) | PT2415771E (sl) |
| RU (1) | RU2529868C2 (sl) |
| SI (1) | SI2415771T1 (sl) |
| TW (1) | TWI471325B (sl) |
| WO (1) | WO2010113942A1 (sl) |
| ZA (1) | ZA201107085B (sl) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012043638A1 (ja) * | 2010-09-29 | 2012-04-05 | キッセイ薬品工業株式会社 | （アザ）インドリジン誘導体及びその医薬用途 |
| NO2686520T3 (sl) * | 2011-06-06 | 2018-03-17 | ||
| CN103889989B (zh) * | 2011-08-24 | 2016-01-20 | 橘生药品工业株式会社 | 稠合杂环衍生物及其制药用途 |
| WO2014065275A1 (ja) | 2012-10-23 | 2014-05-01 | 国立大学法人福井大学 | 腫瘍融解症候群の治療薬及び予防薬 |
| JP2016520133A (ja) * | 2013-05-31 | 2016-07-11 | タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド | キサンチンオキシダーゼ阻害剤を用いた治療方法及びそれを含む組成物 |
| CN114404414A (zh) | 2013-06-13 | 2022-04-29 | 阿克比治疗有限公司 | 用于治疗贫血症的组合物和方法 |
| WO2015123437A1 (en) | 2014-02-13 | 2015-08-20 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| PL3105218T3 (pl) | 2014-02-13 | 2020-03-31 | Incyte Corporation | Cyklopropyloaminy jako inhibitory lsd1 |
| US9493442B2 (en) | 2014-02-13 | 2016-11-15 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| LT3105226T (lt) | 2014-02-13 | 2019-11-11 | Incyte Corp | Ciklopropilaminai, kaip lsd1 inhibitoriai |
| WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| TW201613925A (en) | 2014-07-10 | 2016-04-16 | Incyte Corp | Imidazopyrazines as LSD1 inhibitors |
| WO2016007727A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| WO2016007731A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyridines and imidazopyrazines as lsd1 inhibitors |
| WO2016118858A1 (en) | 2015-01-23 | 2016-07-28 | Akebia Therapeutics, Inc. | Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof |
| BR112017021097B1 (pt) | 2015-04-01 | 2024-01-02 | Akebia Therapeutics, Inc | Formulação de dosagem oral e seu uso |
| EP3277689B1 (en) | 2015-04-03 | 2019-09-04 | Incyte Corporation | Heterocyclic compounds as lsd1 inhibitors |
| SG10202001219UA (en) | 2015-08-12 | 2020-03-30 | Incyte Corp | Salts of an lsd1 inhibitor |
| HUE052608T2 (hu) | 2015-09-02 | 2021-05-28 | Sunshine Lake Pharma Co Ltd | Karboxi-szubsztituált (hetero) aromás gyûrûs származékok, elõállítási eljárásaik és alkalmazásaik |
| CA3018115A1 (en) * | 2015-12-28 | 2017-07-06 | Shanghai Fochon Pharmaceutical Co., Ltd. | Indolizine derivatives, composition and methods of use |
| PE20190377A1 (es) | 2016-04-22 | 2019-03-08 | Incyte Corp | Formulaciones de un inhibidor de lsd 1 |
| AU2017323112B2 (en) * | 2016-09-07 | 2020-11-26 | Haihe Biopharma Co., Ltd. | Pyrido five-element aromatic ring compound, preparation method therefor and use thereof |
| TWI822776B (zh) | 2018-05-09 | 2023-11-21 | 美商阿克比治療有限公司 | 用於製備2-[[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基]乙酸之方法 |
| WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
| CN111943957B (zh) * | 2019-05-17 | 2023-01-06 | 中国医学科学院药物研究所 | 喹啉甲酰胺类化合物及其制备方法和用途 |
| JP2023052711A (ja) * | 2020-03-04 | 2023-04-12 | 国立研究開発法人理化学研究所 | 化合物を放出する方法 |
| AR126164A1 (es) * | 2021-06-17 | 2023-09-27 | Lg Chemical Ltd | Formulación compuesta para dosificación oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico |
| CN115785018A (zh) * | 2022-12-26 | 2023-03-14 | 湖北广济药业股份有限公司 | 一种非布司他脱羧杂质的制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ193926A (en) * | 1979-07-06 | 1984-05-31 | Labaz Sanofi Nv | 2-(alkyl or phenyl)-3(4-hydroxybenzoyl)indolizines |
| FR2779724B1 (fr) * | 1998-06-10 | 2001-04-20 | Rhone Poulenc Rorer Sa | Derives du pyrrole, leur preparation et les compositions pharmaceutiques qui les contiennent |
| CN101282934A (zh) * | 2005-10-07 | 2008-10-08 | 安斯泰来制药株式会社 | 三芳基羧酸衍生物 |
| US7947707B2 (en) | 2005-10-07 | 2011-05-24 | Kissei Pharmaceutical Co., Ltd. | Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same |
| BRPI0810524B8 (pt) | 2007-04-11 | 2021-05-25 | Kissei Pharmaceutical | derivado de (aza)indol, inibidor de xantina oxidase e composição farmacêutica compreendendo o dito derivado |
| MX2009010491A (es) | 2007-04-11 | 2009-11-09 | Kissei Pharmaceutical | Derivado heterociclico de 5 miembros y su uso para propositos medicos. |
| WO2008126901A1 (ja) * | 2007-04-11 | 2008-10-23 | Kissei Pharmaceutical Co., Ltd. | 含窒素複素環化合物およびそれを含有する医薬組成物 |
-
2010
- 2010-03-30 PT PT107587131T patent/PT2415771E/pt unknown
- 2010-03-30 BR BRPI1013432A patent/BRPI1013432B1/pt not_active IP Right Cessation
- 2010-03-30 AU AU2010231615A patent/AU2010231615B2/en not_active Ceased
- 2010-03-30 PL PL10758713T patent/PL2415771T3/pl unknown
- 2010-03-30 MX MX2011010395A patent/MX2011010395A/es active IP Right Grant
- 2010-03-30 EP EP10758713.1A patent/EP2415771B1/en active Active
- 2010-03-30 SI SI201030404T patent/SI2415771T1/sl unknown
- 2010-03-30 DK DK10758713.1T patent/DK2415771T3/da active
- 2010-03-30 CA CA2755132A patent/CA2755132C/en not_active Expired - Fee Related
- 2010-03-30 JP JP2011507210A patent/JP5638513B2/ja active Active
- 2010-03-30 WO PCT/JP2010/055692 patent/WO2010113942A1/ja active Application Filing
- 2010-03-30 RU RU2011143741/04A patent/RU2529868C2/ru not_active IP Right Cessation
- 2010-03-30 KR KR1020117024420A patent/KR101772963B1/ko active IP Right Grant
- 2010-03-30 CN CN201080014876.1A patent/CN102365281B/zh active Active
- 2010-03-30 US US13/259,621 patent/US8748452B2/en active Active
- 2010-03-30 ES ES10758713T patent/ES2429148T3/es active Active
- 2010-03-31 TW TW99109853A patent/TWI471325B/zh not_active IP Right Cessation
-
2011
- 2011-09-28 ZA ZA2011/07085A patent/ZA201107085B/en unknown
-
2012
- 2012-06-29 HK HK12106395.4A patent/HK1165793A1/xx not_active IP Right Cessation
-
2013
- 2013-09-10 HR HRP20130846AT patent/HRP20130846T1/hr unknown
- 2013-10-17 CY CY20131100921T patent/CY1114520T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201107085B (en) | 2012-12-27 |
| CA2755132C (en) | 2018-02-13 |
| HRP20130846T1 (hr) | 2013-11-22 |
| TW201040178A (en) | 2010-11-16 |
| HK1165793A1 (en) | 2012-10-12 |
| US8748452B2 (en) | 2014-06-10 |
| JP5638513B2 (ja) | 2014-12-10 |
| BRPI1013432B1 (pt) | 2019-12-17 |
| CN102365281A (zh) | 2012-02-29 |
| EP2415771B1 (en) | 2013-07-31 |
| WO2010113942A1 (ja) | 2010-10-07 |
| AU2010231615B2 (en) | 2014-05-15 |
| MX2011010395A (es) | 2011-10-24 |
| AU2010231615A1 (en) | 2011-11-03 |
| DK2415771T3 (da) | 2013-10-14 |
| BRPI1013432A2 (pt) | 2016-04-05 |
| CY1114520T1 (el) | 2016-10-05 |
| PT2415771E (pt) | 2013-10-03 |
| JPWO2010113942A1 (ja) | 2012-10-11 |
| RU2529868C2 (ru) | 2014-10-10 |
| KR20110132599A (ko) | 2011-12-08 |
| TWI471325B (zh) | 2015-02-01 |
| EP2415771A4 (en) | 2012-08-29 |
| US20120015972A1 (en) | 2012-01-19 |
| EP2415771A1 (en) | 2012-02-08 |
| CN102365281B (zh) | 2014-11-12 |
| CA2755132A1 (en) | 2010-10-07 |
| PL2415771T3 (pl) | 2014-01-31 |
| RU2011143741A (ru) | 2013-05-10 |
| ES2429148T3 (es) | 2013-11-13 |
| KR101772963B1 (ko) | 2017-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1165793A1 (en) | Indolizine derivative and use thereof for medical purposes | |
| IL216955A0 (en) | Medical devices and methods | |
| HK1206360A1 (en) | (aza)indolizine derivative and pharmaceutical use thereof () | |
| EP2583651A4 (en) | ROLLING CHAIR AND BED | |
| EP2473162A4 (en) | MEDICAL DEVICE WITH EXTENDED USE | |
| EP2468203A4 (en) | MEDICAL DEVICE | |
| EP2471437A4 (en) | MEDICAL DEVICE | |
| EP2471435A4 (en) | MEDICAL DEVICE | |
| HK1170487A1 (en) | Bicyclic compound and use thereof for medical purposes | |
| EP2404540A4 (en) | MEDICAL DEVICE | |
| EP2461691A4 (en) | THERAPEUTIC VITAMIN D SUNSCREEN FORMULATIONS AND METHOD OF USE THEREOF | |
| EP2481355A4 (en) | MEDICAL DEVICE | |
| ZA201201287B (en) | Therapeutic aryl-amido-aryl compounds and their use | |
| GB0918392D0 (en) | Diagnostic and therapeutic methods | |
| EP2515972A4 (en) | MEDICAL DEVICE | |
| EP2390375A4 (en) | ALLOY FOR MEDICAL USE AND MEDICAL DEVICE | |
| GB0920258D0 (en) | New medical agents and use thereof | |
| EP2412288A4 (en) | MEDICAL DEVICE | |
| GB0901795D0 (en) | Medical device and method | |
| GB201209330D0 (en) | Movement monitor and use thereof | |
| GB0908425D0 (en) | Medical use | |
| GB0903187D0 (en) | Medical devices and methods | |
| GB0913300D0 (en) | Therapeutic compounds and their use | |
| GB0900567D0 (en) | Medical device | |
| GB0920881D0 (en) | Medical device |